New Treatment For Low Testosterone Protects Fertility

Online, April 14, 2011 (Newswire.com) - NEW TREATMENT FOR LOW TESTOSTERONE PROTECTS FERTILITY
PAYERS ENDORSE ANDROXAL AS AN EFFECTIVE OPTION

CHATAM, NJ - Reimbursement Intelligence recently put together a market research report in which they interviewed Medical and Pharmacy Directors representing a diverse sample of health plans and covering over 206 million lives.
The report measured payer response to the product Androxal, an orally active drug currently in development by Repros Therapeutics. The product, which has not yet been approved, normalizes testosterone in men. Along with product efficacy, payers were also surveyed on the product versus the current standard of care.
Results showed payers reacted positively toward Androxal. The vast majority of participants, 84 percent, stated that Androxal filled an unmet need in Testosterone replacement. Additionally, 94 percent stated that they would add Androxal to their formulary.
Payers not only responded well to the product's effectiveness but also enjoyed that it is the only drug for low testosterone that is taken orally and has no black box warning. They also recognized the benefits of Androxal because it does not require chronic use and is the only product for low testosterone that protects fertility.

"For men with low testosterone who wish to protect their fertility payers felt Androxal provided an efficacious and safe treatment option," says Rhonda Greenapple, President and Founder of Reimbursement Intelligence.

About Reimbursement Intelligence
Reimbursement Intelligence was built on a commitment to concentrate on biologics, devices and specialty pharmaceuticals in development. For more information on the company's services or to download this article, please visit. www.reimbursementintelligence.com or call Rhonda Greenapple at (973) 805-2300.
Based in Madison, New Jersey, Reimbursement Intelligence is comprised of a group of senior managers with more than 40 years of expertise in defining reimbursement strategy and business planning. The company is uniquely qualified to provide information and services for emerging medical innovations and the biocapital resources that fund them.